LONDON (Alliance News) - AstraZeneca PLC on Monday presented long-term follow-up data from a trial of Calquence in chronic lymphocytic leukaemia patients which showed a sustained a meaningful response to the drug.
The data was presented from Astra's ACE-LY-004 trial in patients with relapsed or refractory forms of this type of cancer. Refractory leukaemia is when some leukaemic cells remain in the patient even after intensive treatment.
The median follow-up was more than two years, with patients showing a sustained a clinically meaningful response to Calquence,
Updated results from the phase one/two ACE-CL-001 trial, which is ongoing, were also presented and showed long-term safety and efficacy of the drug with a high response rate and "no new safety signals identified".
The median time on this trial was 42 months and 89% of chronic lymphocytic leukaemia patients remained on Calquence at the time of analysis.
Shares in AstraZeneca closed up 1.0% at 6,211.00 pence on Tuesday.
Astrazeneca (AZN)